Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. 

Humans produce over 4,000 distinct extracellular proteins, more than 1,000 of which can drive disease when they act improperly, misfold, or are made at the wrong time, in the wrong place, or at incorrect levels. By eliminating these disease-causing proteins, we aim to eliminate diseases for patients.

Molecular Gates act by a completely new therapeutic mechanism. All extracellular proteins pass through single channel in the cell as they are secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the harmful protein is degraded by the cell instead of being secreted.

Our mission to create Molecular Gate medicines is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at www.gatebio.com.

Gate Bioscience

As 2023 draws to a close, we're reflecting on the last 365 days of Gate Bioscience. We're proud of everything our exceptional team has accomplished, and we're profoundly grateful for everyone who's been a part of our journey so far. 

Thank you to all our employees, partners, collaborators, advisors, and investors who have contributed to Gate's momentum this year—and may your 2024 be full of exciting science, discoveries, and growth!

Tune into the Bio Eats World podcast to hear our CEO and cofounder Jordi Mata-Fink talk with Vineeta Agarwala, MD PhD and Ben Portney from a16z Bio + Health about Gate Bioscience and building a novel scientific platform. 

They get geeky about:

 🔬 Extracellular proteins and how they cause diseases
 💊 Why small molecules rock (or, as Vineeta calls them, "the OGs of our therapeutic arsenal")
 🤝 Bringing together the right team
 🚀 The power of a platform in drug discovery
 🍗 Gate's "barbecue of discovery"

Take a listen for all this and more wherever you get your favorite podcasts!

Looking for a podcast for your commute to or from work? 

Tune into Labiotech.eu's latest episode of Beyond Biotech to hear our CEO and Co-Founder, Jordi Mata-Fink, talk with Host Jim Cornall about Gate's science, the promise of Molecule Gate medicines for diseases driven by extracellular proteins, and our vision for this new class of medicines.

🔉 Listen: https://apple.co/3sSdO7f 🔉
🔬 Read more: https://bit.ly/3N3rCmp 🔬

Curious about Gate and our science? Lei Lei Wu has the details in Endpoints News today. 

Check out her article to hear more about the secretory translocon and the powerful potential of Molecular Gate medicines from our Co-Founder and CEO Jordi Mata-Fink and our BOD members and investors Vineeta Agarwala, MD PhD (a16z Bio + Health) and Clare Ozawa (Versant Ventures).

💊 🗞 Click to read more! 💊 🗞

Today’s a big day for Gate Bioscience—we’ve emerged from stealth, unveiling our science, Molecular Gate medicines, our platform, and $60M in funding from Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV (Google Ventures). Come take a look at our press release to learn more about our science, leadership team, and our vision for Molecular Gate medicines. 

https://lnkd.in/efRmE_zJ

Domain Not Resolving

Euro

Amazon

nginx

Java EE

Material-UI

Business Management

Jordi Mata-Fink

Senior Director, Head of Platform Science

David Wyatt

Senior Director of Preclinical Translation

Nina Oberbeck

Nonclinical Study Manager

Eva Situ

Natalie N.

Data Scientist and Statistician

Athena Chen

Chief Scientific Officer

Brian Cathers

Co-Founder and CTO

Raman Talwar

Senior Research Associate - Chemistry

Zachary Owyang

Vineeta Agarwala

Clare Ozawa

Tom Daniel M.D.

Co-Founder and CEO

West Coast Companies With Fewer Than 1000 Employees (Top 10K)

San Francisco Bay Area Early Stage Companies With Fewer Than 1000 Employees

United States Companies With Fewer Than 100 Employees (Top 10K)

San Francisco Bay Area Companies With Fewer Than 1000 Employees (Top 10K)

Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases.

Andreessen Horowitz

Versant Ventures

Series A - Gate Bioscience

Brisbane

California

United States

North America

Gate Bioscience Appoints Industry Veteran Jeff Hatfield to Board of Directors

Genevieve (Gadenne) Sinha on LinkedIn: Can new drugs stop a deadly set of brain-eating diseases?

Gate Bioscience Emerges from Stealth and Introduces Molecular Gates, a New Class of Small Molecule Therapeutics

Protein Archives

Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. The company's mission is to eliminate diseases for patients by targeting disease-causing proteins through a completely new therapeutic mechanism.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 28, 2024 1:51 PM	a33d2ab1
crunchbase profile	general	Oct 29, 2024 5:44 AM	f2d12b78
li profile	general	Feb 2, 2024 11:26 PM	7c7c116b
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	90d48306
peers	general	Feb 2, 2024 11:26 PM	7f68e151
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GATEBIO

Gate Bioscience